Length of metformin exposure | ||||||||
≤1 year vs no | 1–2 years vs no | 2–4 years vs no | >4 years vs no | |||||
aHR* | 95% CI | aHR* | 95% CI | aHR* | 95% CI | aHR* | 95% CI | |
ND | 1.16 | 0.89 to 1.51 | 0.80 | 0.56 to 1.13 | 0.62 | 0.45 to 0.85 | 0.19 | 0.12 to 0.31 |
Dementia | 0.88 | 0.64 to 1.21 | 1.02 | 0.72 to1.44 | 0.55 | 0.38 to 0.79 | 0.22 | 0.13 to 0.37 |
PD | 1.51 | 0.93 to 2.46 | 0.56 | 0.24 to 1.31 | 0.59 | 0.29 to 1.17 | 0.04 | 0.00 to 0.37 |
AD | 2.19 | 1.21 to 3.94 | 0.86 | 0.33 to 2.21 | 0.63 | 0.26 to 1.50 | 0.17 | 0.04 to 0.70 |
Mild cognitive impairment† | 0.86 | 0.19 to 3.81 | 1.50 | 0.36 to 6.19 | 1.43 | 0.41 to 4.95 | 0.78 | 0.19 to 3.19 |
*Non-metformin treatment cohort was the reference group for adjusted HR (aHR) estimation.
†Bad estimation due to small number of events.
AD, Alzheimer’s disease; ND, neurodegenerative disease; PD, Parkinson’s disease; PSW, propensity score weight.